Canada Markets open in 4 hrs 28 mins
  • S&P/TSX

    20,544.11
    -51.78 (-0.25%)
     
  • S&P 500

    4,326.51
    -23.42 (-0.54%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • CAD/USD

    0.7824
    -0.0028 (-0.3591%)
     
  • CRUDE OIL

    87.21
    +0.60 (+0.69%)
     
  • BTC-CAD

    46,754.06
    -193.55 (-0.41%)
     
  • CMC Crypto 200

    829.44
    +9.93 (+1.21%)
     
  • GOLD FUTURES

    1,792.50
    -2.50 (-0.14%)
     
  • RUSSELL 2000

    1,931.29
    -45.18 (-2.29%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,055.50
    +68.75 (+0.49%)
     
  • VOLATILITY

    30.28
    -1.68 (-5.26%)
     
  • FTSE

    7,492.40
    -61.91 (-0.82%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • CAD/EUR

    0.7027
    -0.0015 (-0.21%)
     

Global Osteoarthritis Clinical Trial Pipeline Research Report 2021 - ResearchAndMarkets.com

·2 min read

DUBLIN, December 01, 2021--(BUSINESS WIRE)--The "Global Osteoarthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Osteoarthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Osteoarthritis market. It covers emerging therapies for Osteoarthritis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Osteoarthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Osteoarthritis pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Osteoarthritis pipeline products by the company.

Short-term Launch Highlights:

Find out which Osteoarthritis pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Osteoarthritis phase 3 clinical trial pipeline products

  • Osteoarthritis phase 2 clinical trial pipeline products

  • Osteoarthritis phase 1 clinical trial pipeline products

  • Osteoarthritis preclinical research pipeline products

  • Osteoarthritis discovery stage pipeline products

  • Osteoarthritis pipeline products short-term launch highlights

Key Topics Covered:

1. Osteoarthritis Pipeline by Stages

2. Osteoarthritis Phase 3 Clinical Trial Insights

3. Osteoarthritis Phase 2 Clinical Trial Insights

4. Osteoarthritis Phase 1 Clinical Trial Insights

5. Osteoarthritis Preclinical Research Insights

6. Osteoarthritis Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/mrxoxr

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005786/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting